New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
08:56 EDTPIPPharmAthene price target raised to $6 from $4 at Aegis
Aegis raised Buy rated PharmAthene's (PIP) price target to $6 following the Delaware Court's ruling entitling it to lump sum damages from SIGA Technologies (SIGA).
News For PIP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
10:16 EDTPIPPharmAthene reports Valortim IDIQ contract fulfilled
PharmAthene announced that it has fulfilled its obligations under a fixed price, indefinite delivery, indefinite quantity, or IDIQ, contract, awarded in 2013 by the Biomedical Advanced Research and Development Authority for the company's anthrax anti-toxin, Valortim. Under the IDIQ contract, PharmAthene was selected to provide a specified quantity of its Valortim anthrax anti-toxin master cell bank for secure storage by the government as part of a risk mitigation strategy for anthrax medical countermeasures.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use